ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Angion Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia
June 30, 2021Angion today announced that its exploratory Phase 2 ALI-201 trial of ANG-3777 in patients with severe COVID-19 related pneumonia at high risk for acute respiratory distress syndrome (ARDS) did not meet the primary or secondary efficacy endpoints. -
Angion Biomedica, Sinovant Sciences collaborate to develop BB3
November 19, 2018Angion is currently developing BB3 in a Phase 3 trial for the treatment of delayed graft function (DGF) following kidney transplantation and in a Phase 2 trial for the treatment of acute kidney injury (AKI) following open-heart surgery requiring cardiopul
Pharma Sources Insight January 2025
